At UCB, we want to give people with severe diseases the freedom to live the best life they can - as free as possible from the challenges and uncertainty of disease. We work in a way that is sustainable as we care for the patients who need our solutions, for our employees, for the communities where we live and work, for the health systems we support, for our shareholders, and for the planet.
Early Access / Managed Access Programs
Despite increasing medical innovation, there are still situations where patients with severe, life-threatening, or life-altering diseases do not have sufficient treatment options available to them. Early Access Programs can provide a legitimate path for these patients to access treatments before they are widely available, when a patient’s physician deems it appropriate. Accessing such treatments early may alleviate extreme suffering or potentially save lives of patients with severe diseases. Other terms commonly used to describe these programs are: Expanded Access Programs, Compassionate Use Programs, or Managed Access Programs. National health authorities around the world generally support Early Access if and when the potential benefits to patients outweigh the potential risks.
As a science led, patient-focused company, we strive to secure approval of our products as swiftly as possible to ensure access to our medicines for those patients that need them. Before we reach this stage, UCB’s approach to Early Access allows access to medicines for patients in need, under strictly controlled circumstances prior to local regulatory approval and reimbursement.
Just a moment, the page is loading...
